Latest by Myles Helfand
NeuroAIDS while on efavirenz vs. common NRTIs; HIV and the smoking cessation aid varenicline; PrEP adherence after positive partners start treatment; and Ugandans underreporting their antiretroviral use.
This week: PrEP remains deeply underprescribed in North Carolina; and recent studies explore the effects of inflammation, age, and serum albumin on serious non-AIDS event risk.
This week: the successes of Vancouver's harm reduction and HIV outreach programs; the safety of stem-cell transplantation; how biomarkers predict health events; and how to improve partner notification.
Our latest jaunt through HIV journals looks at a symptom-based scoring system to predict acute HIV, the effect of a person's sex on psychomotor function, and the value of vitamin D supplementation to moderate lipid levels.
Among the research covered this week are fresh findings regarding Jak inhibitors, an exciting experimental class of HIV medications.
In our final installment of 2017, we intermingle forward-looking research with some retrospective analysis. We begin our four-study tour by joining researchers in Tennessee for an exercise in HIV outbreak prediction.
Among this week's selection of four studies, we learn about data from a large study exploring the relative durability of first-line antiretroviral regimens stratified by drug class. (Spoiler alert: Older protease inhibitors don't do so well.)
Among this week's brief tour of recently published studies, we get a reminder about just how deeply mental health can affect an HIV-positive person's clinical care.
Sobering data regarding linkage to HIV care among women in the U.S.; Latinx HIV incidence inequalities; efficacy of hepatitis C treatment among people with HIV; and a call for frequent STI testing among at-risk people with HIV.
This week, we get an important reminder that an HIV-positive person's sense of wellbeing doesn't start and end with an undetectable viral load.